Precision BioSciences (Nasdaq:DTIL) - Hisse Senedi Fiyatı, Haberler ve Analizler

DTIL Stoklara Genel Bakış

Gelişmiş bir gen düzenleme şirketi olan Precision BioSciences, Inc. Amerika Birleşik Devletleri'nde gen eliminasyonu, eklenmesi ve eksizyonu dahil olmak üzere gen düzenlemeleri için in vivo gen düzenleme tedavileri geliştirmektedir. Daha fazla detay

DTIL temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	3/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 94% daha düşük bir oranda işlem görüyor

Bu yıl karlı hale geldi

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 41% oranında düşmesi öngörülüyor

Anlamlı bir piyasa değeri yok ( $56M )

Precision BioSciences, Inc. Rakipler

Puma Biotechnology

NasdaqGS:PBYI

US$147.3m

PharmaCyte Biotech

NasdaqCM:PMCB

US$13.1m

Inhibrx Biosciences

NasdaqGS:INBX

US$203.8m

CytomX Therapeutics

NasdaqGS:CTMX

US$69.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Precision BioSciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$7.26
52 Haftanın En Yüksek Seviyesi	US$19.43
52 Haftanın En Düşük Seviyesi	US$6.41
Beta	1.69
11 Aylık Değişim	-13.26%
3 Aylık Değişim	-25.23%
1 Yıllık Değişim	-36.81%
33 Yıllık Değişim	-97.22%
5 Yıllık Değişim	-98.57%
Halka arzdan bu yana değişim	-98.61%

Son Haberler & Güncellemeler

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31

Precision BioSciences: Uniquely Positioned

Oct 07

Hissedar Getirileri

	DTIL	US Biotechs	US Pazar
7D	0%	2.5%	2.2%
1Y	-36.8%	16.1%	31.6%

Getiri vs. Endüstri: DTIL geçen yıl % 16.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: DTIL geçen yıl % 31.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement	7.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: DTIL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: DTIL 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	108	Michael Amoroso	www.precisionbiosciences.com

Gelişmiş bir gen düzenleme şirketi olan Precision BioSciences, Inc., Amerika Birleşik Devletleri'nde gen eliminasyonu, ekleme ve eksizyon dahil olmak üzere gen düzenlemeleri için in vivo gen düzenleme tedavileri geliştirmektedir. Şirket, DNA genomu ekleme, silme ve onarımı için bir genom düzenleme platformu olan ARCUS'u sunmaktadır. Ayrıca, kronik hepatit B virüsü (HBV) tedavisi için doğrudan kesimler ve düzenlemelerle kovalent olarak kapalı dairesel DNA'yı ortadan kaldırmanın yanı sıra hepatit B yüzey antijeninde uzun süreli azalmalar hedefiyle entegre HBV DNA'yı inaktive etmek için PBGENE-HBV; IND ve/veya CTA sunması beklenen m.3243 ile ilişkili primer mitokondriyal miyopati (PMM) tedavisi için PBGENE-PMM sunmaktadır.

Precision BioSciences, Inc. Temel Bilgiler Özeti

Precision BioSciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
DTIL temel i̇stati̇sti̇kler
Piyasa değeri	US$55.69m
Kazançlar(TTM)	US$11.48m
Gelir(TTM)	US$75.10m

4.9x

F/K Oranı

0.7x

P/S Oranı

DTIL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
DTIL gelir tablosu (TTM)
Gelir	US$75.10m
Gelir Maliyeti	US$0
Brüt Kâr	US$75.10m
Diğer Giderler	US$63.62m
Kazançlar	US$11.48m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	1.50
Brüt Marj	100.00%
Net Kâr Marjı	15.28%
Borç/Özkaynak Oranı	34.3%

DTIL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

DTIL Stoklara Genel Bakış

Ödüller

Risk Analizi

Precision BioSciences, Inc. Rakipler

NasdaqGS:PBYI

US$147.3m

NasdaqCM:PMCB

US$13.1m

NasdaqGS:INBX

US$203.8m

NasdaqGS:CTMX

US$69.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Precision BioSciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Recent updates

Precision BioSciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Price target decreased by 15% to US$2.60

Precision BioSciences, Inc. Announces Management Changes

Consensus revenue estimates increase by 47%

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Price target decreased by 24% to US$5.07

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

Consensus revenue estimates increase by 17%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Less than half of directors are independent

Price target decreased to US$6.63

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought US$60k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Chief Financial Officer recently bought US$51k worth of stock

Consensus forecasts updated

Price target decreased to US$10.63

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population